DS 102

Drug Profile

DS 102

Alternative Names: 15-HEPE; 5-hydroxyeicosapentaenoic acid; AF-102 - Afimmune; DS102

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DS Biopharma
  • Developer Afimmune; DS Biopharma
  • Class Antifibrotics; Lipids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis
  • Phase I Hepatic fibrosis

Most Recent Events

  • 18 Oct 2017 Afimmune receives patent allowance for DS 102 in USA
  • 27 Sep 2016 Phase-II clinical trials in Chronic obstructive pulmonary disease in Ireland (PO)
  • 27 Sep 2016 Phase-II clinical trials in Idiopathic pulmonary fibrosis in Ireland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top